BioSpecifics Technologies Corp.  

(Public, NASDAQ:BSTC)   Watch this stock  
Find more results for Marc Guitman�
-2.04 (-3.06%)
After Hours: 64.64 -0.01 (-0.02%)
Jul 29, 4:05PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 62.85 - 68.32
52 week 25.77 - 71.59
Open 67.01
Vol / Avg. 90,724.00/78,589.00
Mkt cap 446.50M
P/E 74.07
Div/yield     -
EPS 0.87
Shares 6.74M
Beta 0.72
Inst. own 57%
Aug 10, 2015
Q2 2015 Biospecifics Technologies Corp Earnings Release (Estimated) Add to calendar
Jun 1, 2015
Biospecifics Technologies Corp at Jefferies Global Healthcare Conference
May 18, 2015
Biospecifics Technologies Corp at UBS Global Healthcare Conference
May 12, 2015
Q1 2015 Biospecifics Technologies Corp Earnings Call - Webcast
May 11, 2015
Q1 2015 Biospecifics Technologies Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 41.58% 33.00%
Operating margin 63.57% 49.72%
EBITD margin - 50.57%
Return on average assets 28.46% 17.12%
Return on average equity 29.25% 17.67%
Employees 5 -
CDP Score - -


LYNBROOK, NY 11563-2358
United States - Map
+1-516-5937000 (Phone)
+1-516-5937039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioSpecifics Technologies Corp. is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase for marketed indications and collagenase clostridium histolyticum (CCH) for indications in development. Auxilium has an option to acquire additional indications that the Company may pursue, including human and canine lipoma. The Company generates revenue primarily from Auxilium pursuant to the Second Amended and Restated Development and License Agreement with Auxilium (Auxilium Agreement). Under the Auxilium Agreement, the Company receives license, sublicense income, royalties, milestones and mark-up on cost of goods sold payments related to the sale and approval of XIAFLEX.

Officers and directors

Thomas L. Wegman President, Principal Executive Officer, Principal Financial Officer, Director
Age: 60
Bio & Compensation  - Reuters
Mark N. Wegman Ph.D. Director
Age: 65
Bio & Compensation  - Reuters
Toby Wegman Director
Age: 80
Bio & Compensation  - Reuters
Jennifer M. Chao Independent Director
Age: 45
Bio & Compensation  - Reuters
Paul A. Gitman M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
George M. Gould J.D. Independent Director
Age: 77
Bio & Compensation  - Reuters